Yaxiong Zhang

机构：Sun Yat-sen University, Lanzhou University of Technology, Sun Yat-sen University Cancer Center, Department of Forestry, Lanzhou University · ORCID：0000-0002-3632-0300

发表论文 129 篇 · 总被引 4245 次 · h-index 31

代表论文

• BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study (2024 · The Lancet Oncology · 被引 132)
• Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods (2024 · Lung Cancer · 被引 23)
• QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study (2024 · Signal Transduction and Targeted Therapy · 被引 23)
• Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial (2024 · Signal Transduction and Targeted Therapy · 被引 14)
• Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT (2024 · Journal of Clinical Oncology · 被引 9)